The peptide the FDA already voted against

There’s a peptide a lot of people are stacking right now that the FDA has already voted on. Not scheduled to review. Voted. A federal advisory committee sat down with the file, looked at the human safety data, and recommended against it.

You wouldn’t guess that from how this year went. In February a Health Secretary went on the biggest podcast in the world, called himself a big fan of peptides, and said access was coming back. The scene read it as a green light. So it’s worth sitting with the part that didn’t make the clip: if peptides are coming back, why did some of the most popular ones already get a no?

The vote that already happened

CJC-1295. Ipamorelin. Both tell the pituitary gland to release growth hormone. Half of these stacks are built on that pair. They have already been through this committee, and the committee said no.

Ipamorelin went in front of PCAC on October 29, 2024. CJC-1295 went in front of PCAC on December 4, 2024, the same day as AOD-9604 and Thymosin Alpha-1. Each time, the panel voted no on adding the peptide to the 503A bulk drug substances list. That’s the list that decides what a US compounding pharmacy can legally make. The FDA gave the same reason every time: not enough human safety data, concerns about how the drug behaves in the body, and no repeat proof it works outside small or open-label trials. That’s a statement about the evidence, not a verdict on whether these compounds do anything. Right now, there isn’t enough human data to compound them legally.

So the coming-back story has a hole in the middle of it. For a real slice of the most-used peptides, the door everyone thinks is opening was already tried. It didn’t open. A hearing is a decision, not a formality. Sometimes it decides against you. Carry that question into the part everyone’s actually watching: the July meeting, and the peptides still in the running.

What the July meeting is actually deciding

The thing that happened in writing came in April, not February. On April 16, 2026, the Federal Register published notice 2026-07361. It scheduled a Pharmacy Compounding Advisory Committee meeting for July 23 to 24, 2026, to review seven peptides for the 503A bulks list. July 23 covers BPC-157 (reviewed for ulcerative colitis), KPV, TB-500 (wound healing), and MOTs-C. July 24 covers Emideltide (also called DSIP), Semax, and Epitalon (insomnia).

Read those indications again, because they’re the quiet part. BPC-157 is being evaluated for ulcerative colitis, not the shoulder you bought it for. The committee only votes on one named use per peptide. None of the seven is on the docket for the off-label reasons driving most of the demand. So even the best version of July is narrower than the headline made it sound.

We covered how a PCAC review works in what the PCAC review actually is. We covered what happens after a yes vote in what happens after the PCAC votes. Even a yes in July isn’t a prescription you can fill in August. Here’s the short version: PCAC recommends, then the FDA writes the rule. The honest date a US pharmacy could lawfully fill one of these is a 2027 calendar at the earliest.

The peptide the FDA already voted against proves the point. A hearing decides, sometimes against you. Coming back is a direction, not a date. The headline kept the Secretary’s words and dropped the vote that had already happened. The honest version tells you exactly what to watch: not the podcast clip, but the docket. And not the docket alone, but the rule that has to follow it.

The version worth waiting for is the one a US-licensed pharmacy can lawfully compound for a named indication. That means a real prescription, third-party batch testing, and your name on the label. That’s the end-state we’re building toward: reading the docket and the rulemaking that follows it, not the clip. Join the waitlist and we’ll tell you the day a peptide you’re tracking actually gets there.